然而,近年来,有一批HER2表达水平低(HER2-low)的乳腺癌患者引起了研究者的关注。这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 ...
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
Introduction: Breast cancer in young women represents a public health problem with specific age-related issues to be faced by both patients and their treating physicians.Areas covered: This manuscript reviews the recent data on the medical management of young women with early-stage HER2-negative ...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Case 1: Approach to Early Stage, HER2+ Breast Cancer Case 4: Chemotherapy or PARP inhibitors for BRCA+ TNBC Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer Case 4: OlympiAD Trial for BRCA+ Metastatic TNBC Case 4: BRCA+ Metastatic Breast Cancer Case 3: Treatment Afte...
10.Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer. CA A Cancer J Clinicians. 2023;73(5):480-515.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.PubMedGoogle ScholarCrossref 14. Sparano JA, Gray ...
10P - Predictive Value of Serum Thymidine Kinase 1 during Neoadjuvant Chemotherapy in HER2-negative Breast Cancer 血清胸腺嘧啶激酶1在HER2阴性乳腺癌新辅助化疗中的预测价值 讲者:Xintong Zhao(中国,昆明) 12P - A Nomogram Predicting the Long-term Survival Outcome of Neoadjuvant Therapy for Patients with ...
10.Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer. CA A Cancer J Clinicians. 2023;73...
(CPM) in women with average-risk unilateral breast cancer and SLNB in women aged >70 years with HR + , HER2-negative early-stage breast cancer7. Similar to ALND for minimal nodal disease and re-excision for close but negative surgical margins, these practices expose patients to harms ...